Cargando...
Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations
Rheumatoid arthritis (RA) is characterized by chronic synovial inflammation due to unknown causes. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and tofacitinib, a targeted sDMARD, can be used to treat RA. In clinical trials, molecular-targeted...
Gardado en:
| Publicado en: | J Orthop Sci |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer Japan
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4653232/ https://ncbi.nlm.nih.gov/pubmed/26404390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00776-015-0766-9 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|